Design, Synthesis, and In Vitro and In Vivo Biological Studies of a 3′-Deoxythymidine Conjugate that Potentially Kills Cancer Cells Selectively

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wei, Qiong ^a   Zhang, Dejun ^a   Yao, Anna ^a   Mai, Liyi ^a   Zhang, Zhiwei ^b   Zhou, Qibing ^a,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXYTHYMIDINE PHENYLQUINOXALINE CONJUGATE; PHENYLQUINOXALINE; QUINOXALINE DERIVATIVE; SUPEROXIDE; THYMIDINE DERIVATIVE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CELL DIVISION; CONTROLLED STUDY; COVALENT BOND; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL PROLIFERATION; DRUG DESIGN; FLUORESCENCE; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MOLECULAR STRUCTURE; NEOPLASMS; QUINOXALINES; SUPEROXIDES; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 84871563592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052199     Document Type: Article

References (29)

1. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
2. Shen YC, Hsu C, Cheng AL, (2010) Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 45: 794-807.
3. Yuan JN, Chao Y, Lee WP, Li CP, Lee RC, et al. (2008) Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Med Oncol 25: 201-206.
4. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, et al. (1994) Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204-1211.
5. Sherley JL, Kelly TJ, (1988) Regulation of human thymidine kinase during cell cycle. J Biol Chem 263: 8350-8358.
6. Hengstschlager M, Knöfler M, Müllner EW, Ogris E, Wintersberger E, et al. (1994) Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 269: 13836-13842.
7. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G, (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69-89.
8. Arner ES, Eriksson S, (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Therapeut 67: 155-186.
9. Yusa T, Yamaguchi Y, Ohwada H, Hayashi Y, Kuroiwa N, et al. (1988) Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy. Cancer Res 48: 5001-5006.
10. He Q, Mao Y, Wu J, Decker C, Merza M, et al. (2004) Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25: 945-953.
11. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout J L, et al. (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333-8337.
12. Elion GB, (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73(1A): 7-13.
13. Barth RF, Yang W, Wu G, Swindall M, Byun Y, et al. (2008) Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc Natl Acad Sci USA 105: 17493-17497.
14. Morgenroth A, Deisenhofer S, Glatting G, Kunkel FH-G, Dinger C, et al. (2008) Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4′-thio-2′-deoxyuridine. Clin Cancer Res 14: 7311-7319.
15. Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, et al. (2010) A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Therapy 17: 837-843.
16. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM, (2000) Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 44: 496-503.
17. Slamenová D, Horváthová E, Bartková M, (2006) Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung fibroblasts by the antiretroviral drug 3′-azido-3′-deoxythymidine. Mutat Res 593: 97-107.
18. Chen Y-L, Eriksson S, Chang Z-F, (2010) Regulation and functional contribution of thymidine kinase 1 in repair DNA damage. J Biol Chem 285: 27327-27335.
19. Longley DB, Harkin DP, Johnston PG, (2003) 5-Fluorouracil: Mechanism of action and clinical strategies. Nat Rev Cancer 3: 330-338.
20. Van Poecke S, Negri A, Gago F, Van Daele I, Solaroli N, et al. (2010) 3′-[4-Aryl-(1,2,3-triazol-1-yl)]-3′-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem 53: 2902-2912.
21. Lin J, Roy V, Wang L, You L, Agrofoglio LA, et al. (2010) 3′-(1,2,3-Triazol-1-yl)-3′-deoxythymidine analogs as substrates for human and Ureaplasma parvum thymidine kinase for structure-activity investigations. Bioorg Med Chem 18: 3261-3269.
22. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, et al. (2005) Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity. Cancer Res 65: 9047-9055.
23. Zhou Q, Zhang L, Tombes RM, Stewart JK, (2008) Mixed Inhibition of P450 3A4 as a Chemoprotective Mechanism against Aflatoxin B1-Induced Cytotoxicity with cis -Terpenones. Chem Res Toxicol 21: 732-738.
24. Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al. (2010) Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway. Hepatology 51: 535-544.
25. Miltenburger HG, Sachse G, Schliermann M, (1987) S-phase cell detection with a monoclonal antibody. Dev Biol Stand 66: 91-99.
26. Knowles BB, Howe CC, Aden DP, (1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209(4455): 497-499.
27. Lund KC, Peterson LL, Wallace KB, (2007) Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51: 2531-2539.
28. Pérez MJ, Cederbaum AI, (2002) Antioxidant and pro-oxidant effects of a manganese porphyrin complex against CYP2E1-dependent toxicity. Free Radic Biol Med 33: 111-127.
29. Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY, et al. (2011) Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett 301: 212-220.